NCT05961306

Brief Summary

It is known that 1 in 5 women experience psychological difficulties during their pregnancy or in the first year after giving birth. Unfortunately, in 75% of cases, these problems go undetected, resulting in the woman, her partner and the baby not receiving the proper care. For this reason, the Flemish government wants to screen all women in the perinatal period for their mental well-being using short questionnaires with the aim of referring them to appropriate care. Before they can recommend this screening to all women in the perinatal period, it is necessary to investigate the effectiveness of these short questionnaires, as well as the proposed stepped screening protocol. The investigators want to use this study to determine whether the questionnaires and the stepped screening protocol are sufficiently sensitive to detect mental health problems during this period. This means that they want to check whether the (future) moms who screen positive actually have problems and whether the (future) moms who screen negative effectively do not have psychological problems. In case of positive findings, teh investigators want to recommend that screening for psychological well-being should best be part of standard care in the future. Participants will be asked to answer some questions regarding depressive and anxiety symptoms using existing screening instruments (Whooley, GAD-2, EPDS and GAD-7). On the basis of an online application one can be assigned to the group that will be invited for a telephone interview by a study employee of the UZ Gent (psychologist or psyciatrist) to conduct a semi-structured interview within 2 weeks after completing these questions. The interviewer will ask questions about current psychological well-being and, where applicable, psychological problems in the past. The interviewer will not be aware of the responses to the questionnaires, so as not to be prejudiced. Being contacted for an interview does not necessarily mean that those women scored higher on the questionnaires, as they may also belong to the control group. In addition, a number of demographic data are requested (such as age, marital status, level of education, occupational category, how many pregnancies, number of other (living) children, (expected) delivery date, current forms of treatment (medications, psychotherapeutic interventions) and psychiatric history).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2023

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 17, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 27, 2023

Completed
14 days until next milestone

Study Start

First participant enrolled

August 10, 2023

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

October 30, 2024

Status Verified

October 1, 2024

Enrollment Period

1.9 years

First QC Date

July 17, 2023

Last Update Submit

October 28, 2024

Conditions

Keywords

diagnostic accuracy

Outcome Measures

Primary Outcomes (1)

  • anxiety disorders

    SCID-5

    max 2 weeks after screening

Secondary Outcomes (4)

  • depressive episode

    max 2 weeks after screening

  • (hypo)manic episode

    max 2 weeks after screening

  • OCD

    max 2 weeks after screening

  • PTSD

    max 2 weeks after screening

Study Arms (2)

antenatal period

Pregnant women between 20 and 24 weeks of pregnancy will be invited to participate

Diagnostic Test: SCID 5

postnatal period

Moms, 6 to 10 weeks after delivery will be invited to participate

Diagnostic Test: SCID 5

Interventions

SCID 5DIAGNOSTIC_TEST

SCID 5 is a semi-structured standard clinical interview. We will focus on current depressive episode, (hypo)manic episode, anxiety disorders, OCD and PTSD. The interview will be conducted by phone.

antenatal periodpostnatal period

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study will be conducted through 2 hospitals (AZ Groeninge, Kortrijk and AZ St Lucas, Ghent) encouraging their pregnant and/or recently delivered mothers to participate in this study by means of flyers. If there is a shortage of participants, this study can also be spread via the website and social media of https://wolkinmijnhoofd.be (initiative of UZ Gent).

You may qualify if:

  • years or older, antenatal period (20-24 th week of pregnancy) or postnatal period (6 to 10 weeks after birth) and Dutch-speaking.

You may not qualify if:

  • \<18 years, non-Dutch speaking and outside the above mentioned period.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

AZ St Lucas

Ghent, Oost-Vlaanderen, 9000, Belgium

RECRUITING

AZ Groeninge

Kortrijk, West-Flanders, 8500, Belgium

RECRUITING

Related Publications (1)

  • Van Damme R, Van Parys AS, Vogels C, Roelens K, Lemmens GMD. A mental health care protocol for the screening, detection and treatment of perinatal anxiety and depressive disorders in Flanders. J Psychosom Res. 2020 Jan;128:109865. doi: 10.1016/j.jpsychores.2019.109865. Epub 2019 Nov 1. No abstract available.

    PMID: 31838308BACKGROUND

MeSH Terms

Conditions

Depression, PostpartumAnxiety DisordersObsessive-Compulsive DisorderStress Disorders, Post-Traumatic

Condition Hierarchy (Ancestors)

Puerperal DisordersPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesDepressive DisorderMood DisordersMental DisordersStress Disorders, TraumaticTrauma and Stressor Related Disorders

Study Officials

  • Gilbert MD Lemmens, Prof dr

    University Hospital, Ghent

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Rita RA Van Damme, Master

CONTACT

Mathilde ME Descheemaeker, Master

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Weeks
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 17, 2023

First Posted

July 27, 2023

Study Start

August 10, 2023

Primary Completion

June 30, 2025

Study Completion

June 30, 2025

Last Updated

October 30, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations